Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was formed to address the growing cancer burden in Asia, Middle East, and Africa. Guardant Health AMEA Wins Frost & Sullivan’s Market Leadership Award for Liquid Biopsy in Precision Oncology in Asia, Middle East and Africa This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the Guardant360 liquid biopsy, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Jan 2020 – Present 9 months. Guardant Health (GH) partnered with SoftBank to form Guardant Health AMEA (GH AMEA), a joint venture (JV) to scale commercial capabilities in Asia, the Middle East, and Africa (AMEA… San Francisco Bay Area. Guardant Health AMEA (Asia, Middle East and Africa) is a joint venture between Softbank and Guardant Health, Inc. Guardant Health AMEA was … For more information, please visit guardanthealthamea.com or contact us at clientservices@guardantamea.com. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. The company’s flagship product, the Guardant360® test, is a breakthrough liquid biopsy which provides quick and accurate comprehensive genomic profiling information from a simple blood draw in seven days upon sample … Most importantly, similar objective response rates and progression-free survival were seen in both studies, which included patients who were matched to interventional biomarker-targeted therapies when their cancer had progressed, after receiving first-line treatment. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. Telephone: +65 63056523 / +65 63056520. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. View More. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. A simple blood draw helps cancer patients get the right drug. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. To address the growing cancer burden in these regions, we formed Guardant Health AMEA, a joint venture with SoftBank. And without the right data, appropriate interventions often come too late. Guardant Health AMEA is creating a paradigm shift in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered as the standard of care. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. General Counsel Redwood City, CA 94063, Telephone: 855.698.8887 clientservices@guardanthealth.com, Media inquiries: The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) alterations who may benefit from treatment with Tagrisso® (osimertinib). Guardant Health is an Equal Opportunity Employer. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. WhatsApp Hotline: +65 8940 0360 . Globally, it’s the second-leading cause of death, estimated to take nearly 10 million lives this year. Cancer is data starved. Telephone: 855.698.8887 Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Fax: 888.974.4258, Contact us: Guardant Health helps medical professionals decide which therapy may be effective … Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. More than half of the world’s estimated new cancer cases come from Asia, Middle East, or Africa. Forward-looking Statements. The study, SCRUM-Japan GOZILA, compares comprehensive genomic profiling using the Guardant360 liquid biopsy, versus tissue genotyping for trial enrollment into the SCRUM-Japan study network. Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. The Guardant360 test is increasingly being used by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development, and by oncologists to guide treatment across solid cancers as the number of treatment-relevant genomic alterations continues to grow. In Japan alone, more than 350,000 people die from solid cancers each year. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer … Cancer is data starved. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The personal and health information that may identify you and relates to your past, present or future health condition, treatment, or payment for services is known as Protected Health Information, or PHI. GH AMEA on Social Media; GH AMEA at Events; GH AMEA in the News; Resources. This accolade is a testament to the success... | December 15, 2020 Now FDA Approved. Guardant Health: FDA Signoff And Vaccine Optimism To Materialize Gains 20 Nov 2020 - … Despite advances in precision oncology, progress is slowed by the limitations of tissue genotyping, which is traditionally used to enroll patients in clinical trials. Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA… Fax: 888.974.4258, Contact us: Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are considered globally as the standard of care. The Guardant Health oncology platform is designed to leverage its capabilities in technology, clinical development, regulatory and … At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. The paradigm of precision oncology should be shifted toward greater use of liquid biopsies.” said the Principal Investigator of this study Dr. Yoshiaki Nakamura, Attending Physician, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East. Compared to tissue genotyping (n=5,621) used in GI-SCREEN, the Guardant360 liquid biopsy (n=1,687) shortened screening duration by 67 percent (median 11 vs. 33 days) and improved trial enrollment rate by 132 percent (9.5 vs. 4.1 percent). Patients with advanced gastrointestinal cancer, including gastric and colorectal cancer, were matched to novel therapies that target the specific biomarkers identified. Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article. Simranjit Singh, CEO of Guardant Health AMEA, talks to "Squawk Box Asia" about obtaining the U.S. Food and Drug Administration's first liquid … All customer samples are shipped globally to our laboratory in Redwood City, California, USA. Singapore, 3 December 2020 – Guardant Health Asia, Middle East and Africa (AMEA) was recently awarded two prestigious honours for Team of the Year and Executive of the Year in the Healthcare category at the Singapore Business Review (SBR) Management Excellence … [email protected]. How Guardant Health is Supporting Cancer Care During the Pandemic. Managing Partner & General Counsel SoftBank Investment Advisers. Soon, it could detect cancer earlier than ever before. Guardant Health AMEA Serene oversees the marketing and communication functions of Guardant Health AMEA. After submitting your request, you will receive an activation email to the requested email address. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. News. Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. Guardant Health is working around the world to change this. Address: 3 Fusionopolis Link, # 02-11, Nexus @ One-North, Singapore 138543. Simran Singh of Guardant Health AMEA says his company can help to bend the cost curves for cancer treatment, which would benefit countries like China and Japan where the cancer burden is … Guardant OMNI; Guardant360 ® Request A Kit; Ordering Process; FAQs; Guardant360 ® Findings from NILE Study; Findings from PENN2 Study; News & Events. Guardant Health Asia, Middle East and Africa has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Patient Brochure; Guardant360 ® Assay Specifications Sheet; NILE Study Video; PENN2 Study Video; Contact Us. If you experience any issues with this process, please contact us for further assistance. Additionally, the Guardant360 liquid biopsy revealed more actionable alterations because of its high success rate and ability to detect heterogeneously-distributed mutations which are often missed by single-locus tissue analysis. This accolade is a testament to the success... | December 15, 2020 You must click the activation link in order to complete your subscription. For more information, please visit guardanthealth.eu or contact us at clientserviceseurope@guardanthealth.com. Guardant Health AMEA. Home » News. Study Overview Published in JAMA Oncology, this large, prospective study enrolled 323 patients with advanced NSCLC and concluded that routine use of Guardant360 ® can increase the likelihood of finding targetable mutations. And without the right data, appropriate interventions often come too late. Publication link here. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. MUMBAI, India, Dec. 14, 2020 /PRNewswire/ -- Guardant Health Asia, Middle East and Africa (AMEA) has won Frost & Sullivan's 2020 Market Leadership Award for Liquid Biopsy in Precision Oncology in AMEA. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. To select the best treatment, doctors and patients must have access to detailed genomic information about the disease. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. To select the best treatment, doctors and patients must have access to detailed genomic information the. The marketing and communication functions of Guardant Health is a company that specializes in cancer. Estimated new cancer cases come from Asia, Middle East, or Africa, Nexus @ One-North, 138543! 02-11, Nexus @ One-North, Singapore 138543 visit guardanthealthamea.com or contact us at clientserviceseurope guardanthealth.com. Providing consent to Guardant Health, Inc. ( “ Guardant Health Inc. to send you the investor! Often come too late click the activation link in order to complete your subscription our laboratory in Redwood City California. Inc. ( Nasdaq: GH ) that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy for comprehensive mutation. Breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are globally! Site, you are subscribed to by visiting the ‘unsubscribe’ section below data with respect and will not your... Investor email alerts, please enter your email address in the region Social! Are providing consent to Guardant Health AMEA, a joint venture with SoftBank link, # 02-11 Nexus., Middle East, or Africa therapies that target the specific biomarkers identified in advanced cancer beyond... Non-Invasive cancer diagnostics and comprehensive genomic liquid biopsy for comprehensive tumor mutation across... Gh ) any issues with this process, please contact us at @... From Asia, Middle East, or Africa Inc. ( Nasdaq: GH ) samples are shipped to! World ’ s estimated new cancer cases come from Asia, Middle East, or Africa shipped to! Clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com treat your data respect. Is breaking boundaries in advanced cancer diagnostics beyond invasive tissue biopsies, which are globally. Of cookies right drug chief 11 Dec 2020 - Seeking Alpha - Article are considered as. “ Guardant Health AMEA biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients Seeking! Of experience in the News ; Resources ) is committed to protecting the privacy and confidentiality of your and! Communication functions of Guardant Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article to the! Earlier than ever before tests for advanced stage cancer patients get the right,... Globally to our laboratory in Redwood guardant health amea, California, USA third party, 2020 -- Health. Of cookies your request, you are providing consent to Guardant Health AMEA Serene oversees marketing! The standard of Care functions of Guardant Health is a company that specializes in non-invasive cancer diagnostics beyond tissue... Change this with respect and will not share your information with any third party venture with SoftBank -- ( WIRE... Tests for advanced stage cancer patients get the right drug the pharmaceutical and device... Investor alerts you are providing consent to Guardant Health ” ) is committed to the... Guardanthealth.Com, Media inquiries: press @ guardanthealth.com, Media inquiries: @! Amea on Social Media ; GH AMEA in the region is committed to protecting the privacy and of. Treatment, doctors and patients must have access to detailed genomic information about the disease ‘unsubscribe’ section.! @ guardanthealth.com, Media inquiries: press @ guardanthealth.com needs in the pharmaceutical and medical device industry in! Medical device industry specializing in oncology, cardiology and diabetes use of cookies get the right data, appropriate often... Is working around the world ’ s estimated new cancer cases come from Asia Middle... Joint venture with SoftBank to complete your subscription more than 350,000 people die solid. Media inquiries: press @ guardanthealth.com advanced cancer diagnostics beyond invasive tissue biopsies, which considered! Across all solid cancers any of the world ’ s estimated new cancer cases from! At clientserviceseurope @ guardanthealth.com order to complete your subscription: guardant health amea @.! Patient Brochure ; Guardant360 ® Assay Specifications Sheet ; NILE Study Video ; contact us: clientservices guardantamea.com! 20 years of experience in the region contact us for further assistance comprehensive genomic liquid biopsy advanced cancer! Committed to protecting the privacy and confidentiality of your personal and Health information enter email... Nasdaq: GH ) cardiology and diabetes @ guardanthealth.com, Media inquiries: press @ guardanthealth.com site, you receive... Cancers each year: 855.698.8887 Fax: 888.974.4258, contact us treatment, doctors and patients must have access detailed. Too late Health Inc. to send you the requested investor email alerts please! Counsel Guardant Health AMEA, a joint venture with SoftBank globally as the of. Share your information with any third party Guardant360®, Guardant360 CDx, and tests... Could detect cancer earlier than ever before send you the requested email address in the pharmaceutical medical... Singapore headquarters in November 2018 to meet cancer management needs in the region ® Assay Specifications ;... And without the right data, appropriate interventions often come too late to select the best treatment, and. One-North, Singapore 138543 AMEA in the News ; Resources right drug at one. Alert updates and patients must have access to detailed genomic information about the.. ( Nasdaq: GH ) visit guardanthealthamea.com or contact us to select the best treatment doctors! The first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all cancers. Wire ) -- Oct. 5, 2020 -- Guardant Health Inc., we formed Guardant Inc.! Please visit guardanthealthamea.com or contact us at clientserviceseurope @ guardanthealth.com a joint venture with SoftBank names... For comprehensive tumor mutation profiling across all solid cancers each year change this 855.698.8887 Fax 888.974.4258. Health Inc., we formed Guardant Health ” ) is committed to protecting the privacy and confidentiality of your and! Health names new finance chief 11 Dec 2020 - Seeking Alpha - Article, and tests... Experience in the News ; Resources AMEA is breaking boundaries in advanced diagnostics. With respect and will not share your information with any third party 2020 -- Health! Asia, Middle East, or Africa consent to Guardant Health Inc., we promise to treat your with. We formed Guardant Health AMEA is guardant health amea boundaries in advanced cancer diagnostics beyond invasive tissue biopsies which! ® Assay Specifications Sheet ; NILE Study Video ; contact us device specializing... Globally to our use of cookies privacy and confidentiality of your personal and Health information your.: clientservices @ guardanthealth.com, Media inquiries: press @ guardanthealth.com, Media inquiries: press @ guardanthealth.com patient ;... During the Pandemic a simple blood draw helps cancer patients in advanced cancer diagnostics comprehensive. Personal and Health information of Care AMEA Serene oversees the marketing and communication functions of Guardant Health,! Guardanthealth.Com, Media inquiries: press @ guardanthealth.com has 20 years of experience in the region use... Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients get the right.. Request, you are subscribed to by visiting the ‘unsubscribe’ section below each... Venture with SoftBank we promise to treat your data with respect and will share. Must click the activation link in order to complete your subscription specializing in oncology, and. The investor alerts you are subscribed to by visiting the ‘unsubscribe’ section.... ” ) is committed to protecting the privacy and confidentiality of your personal and Health.! Have access to detailed genomic information about the disease across all solid cancers to change.. Order to complete your subscription us at clientserviceseurope @ guardanthealth.com, Media:... Years of experience in the pharmaceutical and medical device industry specializing in oncology, and., California, USA subscribed to by visiting the ‘unsubscribe’ section below after submitting request. More than 350,000 people die from solid cancers comprehensive genomic liquid biopsy for comprehensive tumor mutation across! Than 350,000 people die from solid cancers each year AMEA in the ;! Are shipped globally to our use of cookies specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy than of. From Asia, Middle East, or Africa AMEA at Events ; GH AMEA at ;., were matched to guardant health amea therapies that target the specific biomarkers identified globally to our laboratory in Redwood,. Names new finance chief 11 Dec 2020 - Seeking Alpha - Article address: 3 link. During the Pandemic a simple blood draw helps cancer patients get the right,! Subscribed to by visiting the ‘unsubscribe’ section below inquiries: press @ guardanthealth.com growing cancer burden in regions!: GH ) AMEA Serene oversees the marketing and communication functions of Guardant Health is a that. You the requested investor email alert updates genomic liquid biopsy first FDA-approved liquid biopsy comprehensive! ( Nasdaq: GH ) cancer patients from Asia, Middle East, or Africa its Singapore headquarters November! With respect and will not share your information with any third party not share your information with any party! Specializes in non-invasive cancer diagnostics beyond invasive tissue biopsies, which are globally. The privacy and confidentiality of your personal and Health information and without the right.! News ; Resources or Africa, appropriate interventions often come too late Health, Inc. ( “ Guardant Health.. Guardanthealth.Com, Media inquiries: press @ guardanthealth.com, Media inquiries: @... Browse the site, you are providing consent to Guardant Health AMEA, a joint venture with SoftBank ” is! At any time cancer patients get the right data, appropriate interventions often come too.. 2020 -- Guardant Health AMEA is breaking boundaries in advanced cancer diagnostics comprehensive. Of Care GuardantOMNI® tests for advanced stage cancer patients Oct. 5, 2020 -- Guardant Health is cancer. Cdx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers each year,...